South San Francisco, California
April 14, 2008
Fluidigm Corporation announced today that it has filed a
registration statement with the U.S. Securities and Exchange
Commission (SEC) relating to the proposed initial public
offering of shares of its common stock. Copies of the Fluidigm
Corporation S-1 Registration Statement can be accessed over the
Internet through the SEC's Web site at www.sec.gov. All shares
of the common stock to be sold in this offering are proposed to
be sold by Fluidigm Corporation.
Morgan Stanley & Co. Incorporated is acting as book-running
manager, with UBS Investment Bank and Leerink Swann & Company
acting as co-managers. The number of shares to be offered and
the price range have not yet been determined. This offering will
be made only by means of a prospectus. When available, copies of
the preliminary prospectus relating to this offering may be
obtained from Morgan Stanley & Co. Incorporated’s prospectus
department at 180 Varick Street, New York, NY 10014 or by email
at prospectus@morganstanley.com.
A registration statement relating to these securities has been
filed with the SEC, but it has not yet become effective. These
securities may not be sold, nor may offers to buy be accepted,
prior to the time that the registration statement becomes
effective. This news release shall not constitute an offer to
sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior
to qualification under the securities laws of any such state or
jurisdiction.
Fluidigm Corporation is the creator of the first commercial
integrated fluidic circuit (IFC), and the leading developer,
manufacturer and supplier of IFCs to the life sciences market.
IFCs enable the simultaneous performance of thousands of
biochemical measurements in extremely minute volumes. This
“integrated circuit for biology” achieves unprecedented
miniaturization, integration and automation of sophisticated
liquid handling processes on a single micro fabricated device.
Fluidigm’s IFC systems increase throughput, decrease costs and
enhance sensitivity compared to conventional laboratory systems. |
|
